We scan new podcasts and send you the top 5 insights daily.
Integrating institutional co-investors like the European Investment Bank imposes formal governance on corporate venture entities. Serving public and private partners enforces strict information boundaries, preventing corporate contamination while granting early-stage biotechs protection against unfair corporate terms.
When making a potentially conflicting investment, Thomas Laffont informs the existing founder directly rather than asking for permission. This avoids a scenario where a founder says "no" and the firm proceeds anyway, which would break trust. Direct communication, even with difficult news, is key.
A VC firm's partnership is strongest when all partners can engage in a single, unified investment conversation. Firms with siloed specialists—like separate biotech, consumer, and enterprise partners—risk losing synergy, as there's little point in a partnership if members can't meaningfully debate deals together.
High-performing European biotech VCs struggle to attract institutional capital not because of poor returns, but because the diligence on small funds is inefficient for large pension funds. They prefer writing larger checks to bigger funds, creating a structural barrier for smaller, specialized VCs to get funded.
Early-stage, board-sitting VCs face conflicts investing in rivals. In contrast, late-stage, non-board investors must invest in competitors to make a secular bet on a market, akin to a public market fund buying multiple leaders in a sector.
The biotech venture model is built on syndication, not competition. As a drug progresses, capital requirements balloon to hundreds of millions for late-stage trials, far exceeding any single VC's capacity. This structural reality forces firms to co-invest and partner throughout a company's lifecycle.
When investing in competing late-stage companies, Coatue's policy is to inform the existing founder directly before the new deal closes. They explain their rationale but explicitly do not ask for permission. This approach of radical, direct communication prevents founders from hearing news secondhand and maintains trust, even in potentially contentious situations.
A lead investor's influence can place startup founders in a difficult position, compelling them to accept investments from controversial sources they might otherwise reject. The example of Curie Bio introducing a portfolio company to Boris Nikolic's fund highlights the power imbalance, where founders may lack the leverage to refuse capital for fear of jeopardizing their primary funding relationship.
Firms like Sequoia investing in direct competitors (OpenAI and Anthropic) shows that late-stage venture has evolved. When taking small, non-board seat stakes for hundreds of millions, firms act like public market funds, buying a portfolio of category leaders without the information access that would create a true conflict.
Beyond providing non-dilutive capital, the Flemish government's funding system (VLAIO) includes access to experts who actively challenge a startup's scientific proposals. This process forces strategic rigor and helps refine projects to be more translatable and robust. This built-in expert review is a key advantage of the Belgian biotech ecosystem, making companies smarter, not just richer.
Infinimmune intentionally built a diverse investor base including tech-bio funds, traditional biotech VCs, and corporate venture arms like Merck and Regeneron. This diversity fosters a more "fulsome conversation" in the boardroom, allowing the company to analyze opportunities and challenges from multiple, complementary perspectives.